OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of cancer. The company's lead candidate, OGX-011, is being evaluated in five Phase II clinical trials. OGX-011, which is also known as custirsen sodium, inhibits the production of clusterin, a protein that is over-produced in various types of cancer and in response to a range of cancer treatments, including hormone ablation therapy, chemotherapy, and radiation therapy. Its other product candidates include OGX-427, a Phase 1 clinical trial product, which is focused on reducing heat shock protein 27; and SN2310, a phase I clinical trial completed product for the treatment of cancer. The company's preclinical stage products consist of OGX-225, an inhibitor of insulin growth factor binding proteins 2 and 5; and CSP-9222, a compound from a family of caspase activators. OncoGenex Pharmaceuticals is based in Bothell, Washington.
Contact Details
Office Address
OncoGenex Pharmaceuticals, Inc.
1522 217th Place SE, Suite 100
Bothell, WA, USA 98021
Phone: (425) 686-1500
Fax: (425) 686-1600
Executives
Founder & Chief Exec. Officer
Mr. Scott Daniel Cormack
Chief Financial Officer
Mr. Stephen Anderson
.webp)
.webp)
.webp)
.webp)
.webp)
